Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
Clinical trial NCT05846646 · TERMINATED
Trial details
- NCT number
- NCT05846646
- Sponsor
- ImmuneSensor Therapeutics Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-28
- Primary completion
- 2024-09-16
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.